$PBIO Recent Operational and Technical Highlights Launch

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
232
$PBIO Recent Operational and Technical Highlights

Launch of our Revolutionary UST-Based System to Make High Quality, Water-Soluble Nanoemulsions of CBD Oil

We released a short video demonstrating the ability of our proprietary UST platform to create water-soluble CBD Oil that disperses instantly when infused into soft drinks, sports drinks, and beer for enhanced quality and absorption
We announced our entrance into the CBD market with the launch of a novel processing system (the BaroShear K45) to revolutionize the manufacture of water-soluble, long-term stable, highly absorbable, nanoemulsified CBD Oil
We announced the initial close and customer for our BaroShear K45 nanoemulsification system
We made measurable progress on the build-out of our GMP-compliant manufacturing laboratory, where we expect to showcase the BaroShear K45 and the industrial scale, high volume, 2 liter per minute UST-based nanoemulsification systems

Ohio State/PBIO Project to Develop Safer, More Nutritious, Long Shelf-life, Clean Label Food and Beverages

We achieved the first major milestone in our USDA-funded project to develop a potential breakthrough processing method for higher quality, more nutritious, and safer food and beverages - with a focus on dairy products such as milk. This novel processing method is based on PBIO’s patented Ultra Shear Technology™ (UST™) platform.

Expansion of our Recently Launched BaroFold Contract Services Business

We entered into a six-figure agreement with a multi-national, multi-billion-dollar biopharma company
We continued discussions towards an agreement with a second multi-national, multi-billion-dollar company
We expanded the contract services laboratory with additional specialized equipment and new methods/applications

Expanded Applications for our Core Suite of PCT and Constant Pressure-based Instruments

At the June conference of the American Society for Mass Spectrometry, Dr. Tom Conrads (a nationally-acclaimed protein chemist) spoke on the critical role played by PBI’s Barocycler EXT platform in helping to make the profiling of their Laser Capture Microdissected tumor tissue samples possible at the throughput required in their APOLLO Cancer Moonshot program
Scientists at Tennessee State University showed that PBIO’s HUB instrument platform was highly effective in studies to develop improved methods for food safety, addressing the need for new ways to prevent serious food-borne diseases caused by bacteria such as E. coli and Listeria.

Richard T. Schumacher, President and CEO of PBI, said: “Because of the poor water solubility of today’s oil-based CBD products, most ingested CBD is flushed from the body, leaving little of the product to provide its beneficial properties. After much diligence and analysis, we concluded that we have the expertise and experience to successfully address this critical issue. Consequently, we pulled significant hours away from many of our staff over the past few months and had them focus on the development of an instrument system - based on our patented UST platform - that would increase the water-solubility, and thus the absorption, of CBD Oil. We succeeded; the result of that success is the BaroShear K45 processing system.”

Mr. Schumacher continued: “The CBD market is expected to hit $20 Billion by 2024 (BDS Analytics, 2019). There are currently hundreds upon hundreds of companies in this field. To survive, companies will need to differentiate themselves from the competition by delivering the highest quality products possible. Such products would undoubtedly need to have high water-solubility, absorption, and bioavailability, along with long shelf-life and a minimal amount of added chemicals. This is exactly what we intend to deliver.”

Mr. Schumacher concluded: “We have already begun to pre-sell limited quantities of the BaroShear K45. Units sold over the coming weeks will be delivered and installed in early 2020. We believe that such sales will have a significant impact on 2020 total revenue, potentially resulting in more than twice the total revenue of 2019. We further believe that revenue from our BaroFold platform contract services will continue to increase, and that the decline in PCT platform instrument sales observed over the past two quarters (caused in part by our focus on the development of the BaroShear K45) will end, and that we will see an increase in PCT product sales over the second half of 2019, and beyond.”

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Thursday, August 15, 2019. To attend this teleconference via telephone, Dial-in: (844) 602-0380 (North America), (862) 298-0970 (International). Verbal Passcode: PBIO Second Quarter 2019 Financial Results Call. Replay Number (877) 481-4010 (North America), (919) 882-2331 (International). Replay ID Number: 53312. Teleconference Replay Available for 30 days.

https://www.nasdaq.com/press-release/pressure...0815-00507
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 76

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 92

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 88

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Mynd.ai Alters ADS Ratio Affecting Share Dynamics

Updated Category News Views 82

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

Continue Reading
James Hardie Joins S&P MidCap 400; Roku Acquired

Updated Category News Views 80

A Shift in the MidCap 400: What's Up? Well, wouldn’t you know it, James Hardie Industries is making waves as it steps into the S&P MidCap 400. This move happens because Fox Corp. has nabbed Roku in a deal worthy of some popcorn. Come November 11, when the trading floor wakes up, James Hardie will be in and Roku will be out. Pretty neat switcheroo if you ask me. Inside...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 100

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 96

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 163

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
IRTC Faces Investigation: Shares Plunge Amid Uncertainty

Updated Category News Views 63

Securities Trouble on the Horizon: IRTC Takes a Hit Wake up and adjust your seat, folks—iRhythm Technologies (NASDAQ:IRTC) is in the spotlight, and it ain't pretty. Shares nosedived over 30% in a single morning, stirring up quite the murky waters for shareholders. The trigger? A less-than-stellar third-quarter report. The Numbers Don't Lie—Or Do They? Management...

Continue Reading

Top 5 Most Recently Viewed Articles

ImmunityBio Advances Towards EU Approval for Cancer Treatment

Updated Category News Views 95

ImmunityBio's Journey Towards EU Approval The European Medicines Agency (EMA) has made a significant recommendation toward approving ImmunityBio, Inc.’s Anktiva (nogapendekin alfa inbakicept), intended for use alongside Bacillus Calmette-Guérin (BCG) for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Clinical Trial Results and Findings This...

Continue Reading
Temperature Monitoring Systems Set to Reach $5.66 Billion by 2030

Updated Category News Views 139

Temperature Monitoring Systems Market Analysis and Growth Projections The temperature monitoring systems market, valued at USD 3.80 billion recently, is on a promising trajectory. It is expected to expand at a compound annual growth rate (CAGR) of 5.3%, reaching an impressive USD 5.66 billion by 2030. This growth can be attributed to several factors, including...

Continue Reading
Comparative Insights on Apple and Its Competitors' Performance

Updated Category News Views 336

Performance Insights into Apple and Industry Competitors In the ever-evolving realm of technology, understanding the dynamics of company performance is vital for investors and analysts. This analysis focuses on Apple Inc. (NASDAQ: AAPL) and its key competitors in the Technology Hardware, Storage & Peripherals sector. We'll delve into essential financial metrics, market...

Continue Reading
X Financial Achieves Impressive Growth in Recent Earnings

Updated Category News Views 108

X Financial Reveals Strong Q2 Performance X Financial (NYSE: XYF), a prominent player in the fintech industry, has reported robust financial results that highlight its significant growth and commitment to enhancing its service offering. The company recently disclosed its unaudited financial results for the second quarter, and the figures are quite remarkable. Q2 2025...

Continue Reading
Tyra Biosciences to Engage Investors at Major Conferences

Updated Category News Views 290

Tyra Biosciences to Engage Investors at Major Conferences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a pioneering biotechnology company dedicated to crafting next-generation precision medicines with a keen focus on Fibroblast Growth Factor Receptor (FGFR) biology. The company has great momentum as it takes strides in engaging with investors at a series of crucial investor...

Continue Reading